NASDAQ:VTGN - VistaGen Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.67
  • Forecasted Upside: 178.94 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.39
▼ -0.11 (-4.40%)

This chart shows the closing price for VTGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New VistaGen Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VTGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VTGN

Analyst Price Target is $6.67
▲ +178.94% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for VistaGen Therapeutics in the last 3 months. The average price target is $6.67, with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 178.94% upside from the last price of $2.39.

This chart shows the closing price for VTGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in VistaGen Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/17/2021Robert W. BairdInitiated CoverageBuy$9.00N/A
8/15/2021Robert W. BairdReiterated RatingBuy$9.00Medium
5/19/2021Robert W. BairdInitiated CoverageOutperform$9.00High
2/18/2021Jefferies Financial GroupInitiated CoverageBuy$6.00High
1/4/2021William BlairUpgradeMarket Perform ➝ OutperformN/A
12/22/2020Maxim GroupBoost Price Target$3.00 ➝ $5.00Low
10/8/2020AegisInitiated CoverageBuy$6.00Low
8/11/2020Maxim GroupReiterated RatingBuy$3.00High
6/26/2020Maxim GroupReiterated RatingBuy$1.00Medium
5/29/2020Maxim GroupInitiated CoverageBuy$1.00High
4/29/2020Maxim GroupInitiated CoverageBuy$1.00Low
12/2/2019Chardan CapitalReiterated RatingNeutralHigh
11/14/2019William BlairDowngradeOutperform ➝ Market PerformHigh
11/3/2019Chardan CapitalReiterated RatingHold$0.70Low
10/15/2019Maxim GroupSet Price TargetBuy$4.00N/A
10/9/2019William BlairReiterated RatingBuyN/A
10/8/2019Maxim GroupSet Price TargetBuy$4.00Low
8/28/2019William BlairInitiated CoverageOutperformHigh
7/29/2019Chardan CapitalReiterated RatingNeutralHigh
7/22/2019Chardan CapitalDowngradeBuy ➝ Neutral$22.00 ➝ $0.70High
5/2/2019Maxim GroupSet Price TargetBuy$6.00High
3/6/2019Maxim GroupReiterated RatingBuy$6.00High
11/4/2018OppenheimerSet Price TargetBuy$6.00Medium
10/25/2018Maxim GroupSet Price TargetBuy$6.00Low
10/3/2018Maxim GroupSet Price TargetBuy$6.00High
9/13/2018Maxim GroupSet Price TargetBuy$6.00Medium
9/5/2018Maxim GroupSet Price TargetBuy$6.00Low
9/4/2018OppenheimerSet Price TargetBuy$6.00Low
8/30/2018Maxim GroupSet Price TargetBuy$6.00High
8/24/2018OppenheimerSet Price TargetBuy$6.00Low
8/14/2018Maxim GroupSet Price TargetBuy$6.00High
8/6/2018Maxim GroupSet Price TargetBuy$6.00Low
6/29/2018Chardan CapitalReiterated RatingBuy$22.00Medium
6/27/2018Maxim GroupInitiated CoverageBuy$6.00Low
5/24/2018OppenheimerInitiated CoverageBuy$6.00High
5/24/2018UBS GroupInitiated CoverageOutperform$6.00High
2/8/2018Chardan CapitalLower Price TargetBuy ➝ Buy$30.00 ➝ $22.00Medium
4/27/2017Maxim GroupReiterated RatingBuy$4.00Medium
3/28/2017Maxim GroupInitiated CoverageBuy ➝ Buy$4.00Low
(Data available from 10/18/2016 forward)

News Sentiment Rating

-0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
7/20/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/19/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/18/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
10/18/2021

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
VistaGen Therapeutics logo
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. The company's portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder (SAD); PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD); and AV-101 which the company is developing for the treatment of major depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $2.39
Low: $2.38
High: $2.56

50 Day Range

MA: $2.82
Low: $2.39
High: $3.17

52 Week Range

Now: $2.39
Low: $0.61
High: $3.55

Volume

1,284,100 shs

Average Volume

2,502,510 shs

Market Capitalization

$461.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of VistaGen Therapeutics?

The following sell-side analysts have issued research reports on VistaGen Therapeutics in the last twelve months: Jefferies Financial Group Inc., Maxim Group, Robert W. Baird, William Blair, and Zacks Investment Research.
View the latest analyst ratings for VTGN.

What is the current price target for VistaGen Therapeutics?

3 Wall Street analysts have set twelve-month price targets for VistaGen Therapeutics in the last year. Their average twelve-month price target is $6.67, suggesting a possible upside of 178.9%. Robert W. Baird has the highest price target set, predicting VTGN will reach $9.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $5.00 for VistaGen Therapeutics in the next year.
View the latest price targets for VTGN.

What is the current consensus analyst rating for VistaGen Therapeutics?

VistaGen Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VTGN will outperform the market and that investors should add to their positions of VistaGen Therapeutics.
View the latest ratings for VTGN.

How do I contact VistaGen Therapeutics' investor relations team?

VistaGen Therapeutics' physical mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 577-3600 and its investor relations email address is [email protected] The official website for VistaGen Therapeutics is www.vistagen.com.